Search All UT System Experts

Phase II trial of capecitabine and rHu-interferon-α-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity

Ena Segota, Tarek Mekhail, Thomas Olencki, Thomas E. Hutson, Robert Dreicer, Brenda Wacker, Bruno Osterwalder, Paul Elson, Ming Zhou, Ronald M. Bukowski

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II trial of capecitabine and rHu-interferon-α-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity'. Together they form a unique fingerprint.

Medicine & Life Sciences